Kalinox (Nitrous Oxide, Oxygen)

The nitrous oxide component acts as an NMDA receptor antagonist and modulates GABAergic pathways, producing analgesic and anxiolytic effects. The oxygen component maintains adequate tissue oxygenation, ensuring that patients receive sufficient oxygen while the analgesic effect is achieved.

The dose of Kalinox is individualized by the prescriber based on the patient’s clinical condition, the procedure being performed, and monitoring parameters. The prescribing clinician determines the appropriate concentration and flow rate for each case.

The safety of Kalinox in pregnancy and lactation has not been definitively established. Use should be considered only if the potential benefit justifies any potential risk to the fetus or infant, and it must be decided by the treating physician.

To order Kalinox, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kalinox combines nitrous oxide with oxygen, offering rapid onset analgesia with a built‑in safety margin due to the oxygen component. Compared with pure nitrous oxide, Kalinox reduces the risk of hypoxia, while providing similar analgesic efficacy to other inhalational agents such as sevoflurane for short procedures.

Kalinox cylinders should be stored at ambient temperature in a well‑ventilated, dry area, protected from direct sunlight and extreme heat. Keep cylinders upright, secure them to prevent tipping, and ensure the valve protection caps are in place when not in use.

Kalinox is administered via a calibrated inhalation delivery system, typically a face mask or nasal hood. The clinician adjusts the nitrous oxide/oxygen mixture to achieve the desired analgesic effect while continuously monitoring the patient’s vital signs and oxygen saturation.

Serious risks include hypoxia if the oxygen component is insufficient, severe hypotension, and rare neurological toxicity with prolonged exposure. Immediate recognition of these events and prompt supportive measures are essential to mitigate complications.

Kalinox should not be used in patients with known hypersensitivity to nitrous oxide, those with severe respiratory compromise, or individuals for whom adequate oxygenation cannot be guaranteed. It is also contraindicated in patients receiving certain high‑dose sedatives without close monitoring.